Therefore, CS alleviates COPD symptoms means that CS treatment reduced sputum inflammatory cells (p < 0.01), decreased serum IL‐6 (p < 0.05), and improved forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) ratio (p < 0.01) compared to controls. The gene discussed is IL6; the disease is chronic obstructive pulmonary disease.